



**Sarepta Therapeutics to Host Webcast and Conference Call for the Duchenne Muscular Dystrophy Community on December 2, 2014**

CAMBRIDGE, Mass. -- (BUSINESS WIRE) -- Nov. 24, 2014-- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, will host a webcast and conference call for the Duchenne muscular dystrophy (DMD) community on Tuesday, December 2, 2014, beginning at 11:00 a.m. EST (8:00 a.m. PST / 4:00 p.m. GMT / 5:00 p.m. CET).

Chris Garabedian, president and chief executive officer, and Edward Kaye, M.D., chief medical officer, will provide information and answer questions about Sarepta's DMD development program, including current and upcoming clinical trials. Sarepta has invited DMD community representatives from leading patient advocacy groups to participate in the question and answer portion of the webcast.

To access the webcast, visit the events and presentations section of Sarepta's website at [www.sarepta.com/events](http://www.sarepta.com/events) and follow the link for the webcast under "Upcoming Events." Please connect several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

To access only the audio portion, dial in to (800) 708-4540 for U.S. callers or (847) 619-6397 for international callers. The passcode for the call is 38547268. Please specify to the operator that you would like to join the "Sarepta DMD Community Update."

Following the event, the webcast will be archived in the events and presentations section of Sarepta's website for 90 days.

**About Sarepta Therapeutics**

Sarepta Therapeutics is focused on developing first-in-class RNA-based therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases. Sarepta's diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy, as well as potential treatments for some of the world's most lethal infectious diseases. Sarepta aims to build a leading, independent biotech company dedicated to translating its RNA-based science into

transformational therapeutics for patients who face significant unmet medical needs. For more information, please visit us at [www.sarepta.com](http://www.sarepta.com).

### **Internet Posting of Information**

We routinely post information that may be important to investors in the 'For Investors' section of our web site at [www.sarepta.com](http://www.sarepta.com). We encourage investors and potential investors to consult our website regularly for important information about us.

Source: Sarepta Therapeutics, Inc.

Sarepta Investors:

Stephanie Ascher, 212-362-1200

[stephanie@sternir.com](mailto:stephanie@sternir.com)

or

Sarepta Media:

Tony Plohoros, 908-591-2839

[tplohoros@6degreespr.com](mailto:tplohoros@6degreespr.com)

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company’s Securities and Exchange Commission filings.